Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Pfizer

Healthcare stocks are a staple of every portfolio. With an ageing population, healthcare stocks are here to stay.

Pfizer Vs. Merck Vs. AbbVie Vs.

Aflac

Bayer AG

Bristol-Myers

Bank of Nova Scotia

Cisco Systems

Federal Realty Investment Trust

General Dynamics

Intel

Prudential Financial

Simon Property Group

Unum

The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into December 2020. Rather than offering some sort of collective "list" that could potentially be hard to offer a clear overview, I go sector by sector and present 1-2 alternatives.

December 2020 Stocks: Financials, Real Estate, Industrials, IT, And Pharma

In August, analysts and investors were wondering what Bristol-Myers Squibb Co. (NYSE:BMY) could do to reverse the sales decline for one of its blockbuster drugs. This is certainly a legitimate concern considering revenue from the company's cancer treatment, Optivo, declined 9% year over year in the second quarter and another 2% in the three months ending Sept.

New Uses Could Boost Sales of Bristol-Myers and Merck Drugs

Merck owns one of the best drugs in the world, Keytruda. The company has a solid growth outlook going forward.

Buffett Buys Merck - And You Should, Too

United Rentals

MADISON HEIGHTS, Mich., Dec. 3, 2020 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced United Rentals Inc. (NYSE: URI) as its "Stock to Study" and Merck & Co., Inc. (NYSE: MRK) its "Undervalued Stock" in the March 2021 issue...

BetterInvesting™ Magazine Chooses United Rentals As "Growth" Stock and Merck As "Undervalued" For March 2021 Issue

Covetrus Inc

FactSet Research Systems

Henry Schein

Nestle SA

Zoetis

More households own pets than have children, and they'll pay to keep their furry friends happy. Here are 6 big pet stocks.

85 Million & Climbing: Why Pets = Profits for These 6 Companies

Moderna

It's tempting, but it could also be a mistake.

Merck Just Sold Off Its Moderna Shares for a Huge Gain. Should You?

Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets Artios to receive US$30 million in up-front and near-term payments,...

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

One investor cashing in on Moderna's meteoric rise in 2020 is Merck, the New Jersey-based pharmaceutical giant. In a statement on Wednesday, Merck said it sold its equity stake in Moderna in the first half of the fourth quarter, adding that it achieved a "substantial gain" on its holdings.

Merck sells its $175 million investment stake in Moderna after recording a 'substantial' gain (MRNA)

BioNTech SE

COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.

COVID-19 Vaccines Are on the Way and Major Players Are Cashing In

U.S. pharma giant Merck & Co., Inc. (NYSE: MRK) announced Tuesday ahead of the market open that it divested its direct stake in Moderna Inc (NASDAQ: MRNA) in the first half of the fourth quarter. Merck initiated a direct investment in the vaccine developer in 2015 and hiked the stake in 2018, in accordance with an R&D collaboration agreement executed between the companies.

Merck Cashes Out Direct Investment In Moderna After 600% Year-To-Date Stock Gain

Encouraging News on COVID-19 Vaccine

U.S. drugmaker Merck & Co said on Wednesday it had sold its equity investment in vaccine developer Moderna Inc.

Drugmaker Merck divests investment in Moderna

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference

Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Altria

Philip Morris

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The December 2020 Heat Map

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

Merck recently announced it is buying OncoImmune for $425 million in cash. These are the details about the deal.

Why Merck (MRK) Is Buying OncoImmune For $425 Million

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

JPMorgan Chase & Co

American Airlines

They may be down this year, but don't count these stocks out for a rally in 2021.

3 Cheap Stocks to Buy Before the Economy Makes a Full Recovery

MRK stock has entered a new swashbuckling era, searching for new profit gushers like Keytruda, the company's anti-cancer drug. The post Merck and Biotech's Swashbuckling Era appeared first on InvestorPlace.

Merck and Biotech's Swashbuckling Era

Amgen

Salesforce

Goldman Sachs

Home Depot

Johnson & Johnson

McDonald's

Microsoft

UnitedHealth Group

Dow 30,000 is great. But a Dow Jones at 31,659 is even better — and that's where the Blue Chip average is headed in 12 months, analysts say.

9 Stocks Seen Propelling Dow To 31,662

Enterprise Products Partners

Realty Income Corp

Shaw Communications

STAG Industrial

Exxon Mobil

From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 dividend equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; 15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+ Year Dividends'; and '11 Monthly-Pay Stocks/Funds.'

Of 56 Kiplinger Outstanding Dividend Stocks, 11 Show Sweetness For December

News for Merck Stock (MRK)